Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...

The US regulator has cleared the new 8 mg formulation of Eylea (aflibercept) for patients with wet age-related macular degeneration (AMD), diabetic macular oedema (DME), and diabetic retinopathy ...

Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...

Alvotech is also developing AVT29, a biosimilar to the higher dose of Eylea (8 mg), with Teva holding commercialization rights for both AVT06 and AVT29 in the U.S. TEVA closed Friday's (Feb.14 ...

driven by increased demand for Eylea HD (aflibercept 8 mg), Libtayo (cemiplimab), its key medication in the oncology franchise, as well as revenue growth from its collaboration with Sanofi (SNY ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also holds commercialization rights for AVT29 in the U.S. Eylea ® is a widely used biologic for the treatment of eye disorders, such as ...